Ogunsen

Ogunsen

Sälj aktien Köp aktien Handla aktien direkt på nordnet

« Tillbaka

Ogunsen - Some signs of stabilisation

23 augusti 2026

  • Positive organic growth will take time
  • We slightly lower our sales estimates due to a reduction in FTEs
  • Trading ~10% below peer median

Q2'26 report

Ogunsen reported Q2'26 sales of SEK 108m, marking a y-o-y decrease of 3%. It is worth keeping in mind that returning to positive growth is tough for consulting firms, as growth depends on billable hours, which is affected by lower headcount, and average FTEs at Ogunsen are down to 362 from 370 a year ago. Demand in the consulting segment was stable y-o-y, although fewer consultants, slightly lower utilisation and lower hourly rates weighed on sales. Recruitment demand remained slightly below last year but improved sequentially, indicating tentative signs of stabilisation. Adj. EBIT came in at SEK 4.6m (3.3m in Q2'25), with a higher margin of 4.3% (3.0%), likely driven by some cost control at the company.

Slightly lowering our sales estimates

The market remains tough, and we slightly lower our sales estimates by 4% for '26e-'28e on the back of the report. Consequently, we also lower our adj. EBIT estimates by 28% for ’26e, as lower sales and fewer billable FTEs result in negative operating leverage, partly offset by continued cost control. A recovery in the consulting market will likely take time, with stronger margins eventually following from that.

Getting better, but it takes time

Ogunsen is trading at 10x-5x EV/adj. EBIT for '26e-'28e, ~10% below the peer median valuation. We see some demand KPIs improving, but we emphasise that Swedish wage agreements push salaries higher every year, so margin expansion remains a challenge in this environment. What still needs to return, in our view, is demand at normalised levels, along with positive net recruitment and room for price increases. That said, the improving demand trend and a leaner cost base provide a more supportive foundation for a gradual recovery.

Senaste artiklar från alla bolag

Datum Titel Bolag Typ
2026-08-25 Isofol Medical - Maximising the dose before Phase 2 Isofol Medical Analys
2026-08-24 Skolon - Broad-based growth continues Skolon Analys
2026-08-24 Gentoo Media - FCF generation remains top priority Gentoo Media Analys
2026-08-24 Impact Coatings - Backlog to carry H2e Impact Coat.. Analys
2026-08-24 I-tech - Beyond a single molecule I-tech Analys
2026-08-23 Catella - Signs of improvement, but delivery stil... Catella Analys
2026-08-23 Ogunsen - Some signs of stabilisation Ogunsen Analys
2026-08-21 Clavister - Strong quarter strengthens the outlook Clavister Analys
2026-08-21 Generic - Investing while growing Generic Analys
2026-08-21 Impact Coatings - A quarter driven by Coating Ser... Impact Coat.. Analys
2026-08-21 Skolon - Sweden profitability gains continue Skolon Analys
2026-08-21 I-tech - Strongest quarter on record I-tech Analys
2026-08-20 Tempest Security - Patrols below plan Tempest Sec.. Analys
2026-08-20 Tempest Security - Progress made but expectations... Tempest Sec.. Analys
2026-08-20 Ascelia Pharma - Still alive: Fighting to reverse... Ascelia Pharma Analys
2026-08-20 Clavister - Defence drives record quarter Clavister Analys
2026-08-20 Catella - Q2 softer than expected, but underlying... Catella Analys
2026-08-20 Generic - Volumes continue to grow Generic Analys
2026-08-19 SinterCast - Past the trough, but recovery pace u... SinterCast Analys
2026-08-19 Xplora Technologies - EBITDA -13% on soft senior ... Xplora Tech.. Analys